BiologicalSupplement

Myrciaria dubia clinical trials

studies test it: 3
open now: 0
in phase 3: 0
first study started: 2020

How each study uses Myrciaria dubia is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

Studies by the year they started

3 studies that test it; most in 2020 (2)

Studies that test Myrciaria dubia, by start year
Year	Studies
2020	2
2022	1

By phase

A phase 1/2 study counts in both.

Phase 1: 2
No phase: 1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung: 1
HIV Infections: 1
Overweight: 1

Who runs them

Industry 0 · Other 3

Centre hospitalier de l'Université de Montréal (CHUM) (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Laval University (1)

Often tested with

Tested in the same studies.

Camu-camu fruit (3)

Studies

Open first, then newest update. How each study uses Myrciaria dubia is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.